Citations

Clear

367 citation(s) found for "Su, Pan".

TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).
Goto, Yasushi , Levy, Benjamin , Rixe, Olivier , Yang, Tsung‐Ying , Lou, Yanyan , Zenke, Yoshitaka , Savvides, Panos, Dómine, Manuel , Leventakos, Konstantinos , Horiike, Atsushi , Lin, Daisy, Gu, Jessie, Basak, Priyanka , Paz‐Ares, Luis , Su, Wu‐Chou , Tolcher, Anthony W. , Savvides, Panos, Felip, Enriqueta , Pan, Edward , Basak, Priyanka, Chisamore, Michael Jon

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: 9004-9004

10.1200/jco.2023.41.16_suppl.9004 Get It

9004 Background: Despite advances in first-line (1L) immunotherapy ± CT, most patients (pts) with aNSCLC experience disease progression, necessitating novel strategies. Dato-DXd is an antibody drug conjugate (ADC) composed of a humanized anti-TROP2 IgG1 monoclonal antibody covalently linked to a topoisomerase I inhibitor payload via a plasma-stable tetrapeptide-based cleavable linker. Dato-DXd had encouraging efficacy and manageable safety in heavily pretreated aNSCLC. Dato-DXd + immunotherapy yielded greater preclinical activity than either agent alone. Methods: TROPION-Lung02 (NCT04526691) is a phase 1b, global, dose-escalation and -expansion study evaluating Dato-DXd (4 or 6 mg/kg) + pembro 200 mg ± Pt-CT (cisplatin 75 mg/m2 or carboplatin AUC 5) every 21 days across 6 cohorts. Pts in escalation may have received ≤2 prior lines of therapy for aNSCLC. Pts in expansion were primarily treatment (tx) naive (pts receiving Dato-DXd + pembro may have ≤1 prior Pt-based tx). The primary objective is to assess safety and tolerability, including dose-limiting toxicities (DLTs). Secondary objectives include evaluation of efficacy, pharmacokinetics, and immunogenicity. Results: As of the Oct 31, 2022, data cutoff (DCO), 120 pts were treated. All cohorts met DLT criteria to move to escalation. Median age was 65 years. PD-L1 expression was <1%, 1%-49%, and ≥50% in 40%, 33%, and 26% of pts, respectively. Median tx duration was 4.6 mo, with 55% receiving tx at DCO. The most frequent any-grade (gr) tx-emergent adverse events (TEAEs) were nausea (45%) and stomatitis (45%). Gr ≥3 TEAEs occurred in 61% of pts; most frequent were neutrophil count decreased (8%) and amylase increased (8%). TEAEs that were serious, associated with discontinuation, or associated with death occurred in 31%, 24% (16% associated with Dato-DXd), and 6% of pts, respectively. Dose reductions due to TEAEs associated with Dato-DXd occurred in 17%. Drug-related interstitial lung disease occurred in 12 pts (10%; 9 gr 1/2; 3 gr 3). The objective response rate (ORR) with 1L Dato-DXd + pembro doublet and Dato-DXd + pembro + Pt-CT triplet tx was 60% (95% CI, 36%-81%; 12 [2 unconfirmed]/20) and 55% (95% CI, 39%-70%; 23 [5 unconfirmed]/42), respectively. The ORR for any line of therapy was 38% (95% CI, 25%-54%; 18 [2 unconfirmed]/47) with doublet and 47% (95% CI, 34%-60%; 28 [5 unconfirmed]/60) with triplet tx. In both subsets, the disease control rate was 85% and median duration of response was not reached. Responses were observed in all 3 PD-L1 expression level subgroups. Although immature, median progression-free survival (95% CI) was 10.8 (8.3-15.2) and 7.8 mo (5.5-NE) with doublet and triplet tx, respectively. Conclusions: Dato-DXd + pembro ± Pt-CT demonstrated tolerable safety with notable 1L activity in this first and largest dataset with an ADC + immunotherapy ± Pt-CT in aNSCLC pts. Clinical trial information: NCT04526691 .
CheMo4METPANC: A phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) Motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in metastatic treatment-naïve pancreas adenocarcinoma.
Manji, Gulam A. , Pellicciotta, Ilenia, Ana, Sarah Sta , Sender, Naomi , Pan, Samuel , Ross, Isabelle, Raufi, Alexander G. , May, Michael S. , Hu, Jianhua , Shi, Qian

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: TPS4200-TPS4200

10.1200/jco.2023.41.16_suppl.tps4200 Get It

TPS4200 Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) is a uniformly fatal disease for which treatments result in limited benefit. Failure of immune checkpoint blockade is attributed to multiple immunosuppressive pathways within the tumor microenvironment. The C-X-C motif chemokine receptor 4 (CXCR4)/C-X-C motif chemokine ligand 12 (CXCL12) axis results in exclusion of anti-tumor immune cells. Preclinical studies demonstrated that simultaneous CXCR4 inhibition (CXCR4i) and anti-programmed cell death 1 (aPD1) resulted in tumor stabilization. We extended these findings by testing multiple combinations of CXCR4i, aPD1, and gemcitabine in the KPC mouse model of PDAC. Mice treated with gemcitabine, CXCR4i, and aPD1 (triple therapy) experienced a survival benefit compared to mice treated with either gemcitabine alone, or with CXCR4i/aPD1. Tumors from mice treated with triple therapy demonstrated increased apoptosis and a favorable tumor immune microenvironment (TIME). Motixafortide with pembrolizumab, fluorouracil, and nanoliposomal irinotecan has shown encouraging results in the second-line setting in mPDAC with a confirmed ORR of 13.2% and progression free survival (PFS) of 3.8 months (m). The goal of this first-in-man trial is to test preliminary safety and efficacy of Motixafortide (CXCR4i), Cemiplimab (aPD1), Gemcitabine, and Nab-paclitaxel (MCGN) in treatment naïve mPDAC. Methods: This is an open label, multicenter, investigator-initiated simon-2-stage phase 2 clinical trial in mPDAC testing MCGN. The study includes a six-patient safety run-in cohort and an additional 4 patients comprising a pilot efficacy signal seeking study (N=10). If ≥3 of the 10 patients within the pilot stage were to experience a partial response (PR) by RECIST criteria within 16 weeks, the combination would be considered promising and an expansion cohort of an additional 30 patients was planned. On 09/21/22, we amended the study to forego the planned open-label expansion cohort (N=30) and transition directly to a randomized phase 2 trial testing MCGN compared toGemcitabine and Nab-paclitaxel (GN) alone (N=102), after completion of the pilot phase of the study. The primary endpoint is PFS. The study has 80% power to detect an improvement in PFS from 6 to 9.2 m (HR 0.65) with a one-sided alpha of 0.20. One interim analysis for futility is planned when 50% of the PFS events are observed. Secondary objectives include ORR, disease control rate, duration of clinical benefit and OS. Required (pilot portion) and optional (randomized portion) paired tumor biopsies will undergo exploratory analysis including interrogation of the TIME. This trial was started in September 2020 and has enrolled 10 patients to the pilot stage as of 02/2023. Clinical trial information: NCT04543071 .
Using EHR data and machine learning approach to facilitate the identification of patients with lung cancer from a pan-cancer cohort.
Yu, Yue , Ruddy, Kathryn J. , Leventakos, Konstantinos , Liu, Bolun , Pachman, Deirdre R. , Zong, Nansu , Jiang, Guoqian , Liu, Bolun , Huo, Nan , Xiao, Guohui , Chute, Christopher G. , Pfaff, Emily , Cheville, Andrea

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: e13552-e13552

10.1200/jco.2023.41.16_suppl.e13552 Get It

e13552 Background: Real-world data from Electronic Health Records (EHR) have been widely used for patient identification to build study cohorts for clinical research. Traditionally, diagnosis codes in the EHR, such International Classification of Diseases (ICD), are used to identify the target patients. However, the accuracy of this approach is dependent on the accuracy of ICD coding, with potential errors especially for tumor types that are frequent locations for metastases (which may contribute to mis-coding). In this study, we attempted to develop a Machine Learning (ML) based approach on EHR data to improve the accuracy of identification of patients with lung cancer. Methods: We used survey respondents in the Enhanced, EHR-facilitated Cancer Symptom Control (E2C2, NCT03892967) cluster-randomized trial at Mayo Clinic as our initial pan-cancer cohort. E2C2 includes adults receiving Medical Hematology/Oncology care for a solid or liquid tumor at Mayo Clinic. We collected cancer diagnoses from the individually abstracted Mayo Clinic Cancer Registry to annotate the cancer type for the patients. Lung cancer related ICD-9 (162.X) and ICD-10 (C34.X) codes were used to build a search query on the Mayo’s EHR to find target patients from the E2C2 cohort, and to investigate the ICD-based lung cancer patient identification performance. Diagnosis, radiation oncology treatment (CPT 77261 - 77799), and antineoplastic drug administration data were collected from EHR as variables. Logistic Regression (LR), Support vector machine (SVM), Random Forest (RF), and eXtreme Gradient Boosting (XGB) were selected to build models for lung cancer patient identification. 10-fold cross-validation was implemented to assess the models. Precision, Recall, F1 Score, and area under the curve (AUC) were selected to measure the performance. Results: We collected 13,893 patients with a specific cancer diagnosis, and 1,394 were identified as having lung cancer. The identification performance across different methods is shown. The ICD-based method only had 0.65 precision. It means we collected a lot of false positive cases (other cancer but no lung cancer patient), as we mentioned in the background. SVM gets the best precision results, but its recall and F1 score are not good enough. XGB shows the best F1 Score and AUC, which also means this method achieved the best and most balanced performance. Conclusions: In this study, we found that XGB-based methods achieved the best identification performance for lung cancer. In the future, we will investigate if this is also true for the identification of other cancer types. [Table: see text]
Evidence for Angiotensin II as a Naturally Existing Suppressor for the Guanylyl Cyclase A Receptor and Cyclic GMP Generation
Ma, Xiao , Ma, Xiaoyu , Reginauld, Shawn, Chen, Yang , Pan, Shuchong, Zheng, Ye , Moroni, Dante , Yu, Yue , Zhang, Lianwen , Cannone, Valentina , Chen, Horng H. , Ferrario, Carlos M. , Sangaralingham, S. Jeson , Burnett, John C. , Iyer, Seethalakshmi R., Reginauld, Shawn H, Moroni, Dante G, Ferrario, Carlos M , Ma, Xiao , Iyer, Seethalakshmi , Sangaralingham, S. Jeson

Mayo Clinic

International Journal of Molecular Sciences | May 11, 2023 | Volume: 24 | Issue: 10 | Pages: 8547

10.3390/ijms24108547 | PMID 37239899 Get It

The natriuretic peptide system (NPS) and renin-angiotensin-aldosterone system (RAAS) function oppositely at multiple levels. While it has long been suspected that angiotensin II (ANGII) may directly suppress NPS activity, no clear evidence to date supports this notion. This study was designed to systematically investigate ANGII–NPS interaction in humans, in vivo, and in vitro. Circulating atrial, b-type, and c-type natriuretic peptides (ANP, BNP, CNP), cyclic guanosine monophosphate (cGMP), and ANGII were simultaneously investigated in 128 human subjects. Prompted hypothesis was validated in vivo to determine the influence of ANGII on ANP actions. The underlying mechanisms were further explored via in vitro approaches. In humans, ANGII demonstrated an inverse relationship with ANP, BNP, and cGMP. In regression models predicting cGMP, adding ANGII levels and the interaction term between ANGII and natriuretic peptides increased the predictive accuracy of the base models constructed with either ANP or BNP, but not CNP. Importantly, stratified correlation analysis further revealed a positive association between cGMP and ANP or BNP only in subjects with low, but not high, ANGII levels. In rats, co-infusion of ANGII even at a physiological dose attenuated cGMP generation mediated by ANP infusion. In vitro, we found the suppressive effect of ANGII on ANP-stimulated cGMP requires the presence of ANGII type-1 (AT1) receptor and mechanistically involves protein kinase C (PKC), as this suppression can be substantially rescued by either valsartan (AT1 blocker) or Go6983 (PKC inhibitor). Using surface plasmon resonance (SPR), we showed ANGII has low binding affinity to the guanylyl cyclase A (GC-A) receptor compared to ANP or BNP. Our study reveals ANGII is a natural suppressor for the cGMP-generating action of GC-A via AT1/PKC dependent manner and highlights the importance of dual-targeting RAAS and NPS in maximizing beneficial properties of natriuretic peptides in cardiovascular protection.
Country-level gender inequality is associated with structural differences in the brains of women and men
Alliende, Luz María , Medel, Vicente , Bethlehem, Richard A. I. , Ringlein, Grace , Arango, Celso , Asmal, Laila , Bellgrove, Mark A. , Bernardo, Miquel , Billeke, Pablo , Bosch‐Bayard, Jorge , Busatto, Geraldo F. , Castro, Mariana N. , Chaim-Avancini, Tiffany , Compte, Albert , Costanzi, Monise , Dazzan, Paola , Fuente‐Sandoval, Camilo de la , Díaz‐Zuluaga, Ana M. , Duran, Fábio , Fittipaldi, Sol , Fornito, Alex , Freimer, Nelson B. , Gadelha, Ary , Gama, Clarissa Severino , Ramesh, Ranjini Garani , García‐Rizo, Clemente , Campo, Cecilia González , González‐Valderrama, Alfonso , Holla, Bharath , Ibáñez, Agustín , Ivanovic, Daniza , Jackowski, Andrea Parolin , Löchner, Christine , López‐Jaramillo, Carlos , Massuda, Raffael , McGuire, Philip , Murray, Robin , Özerdem, Ayşegül , Pan, Pedro Mário , Parellada, Mara , Phahladira, Lebogan, Ramírez-Mahaluf, Juan Pablo , Reyes-Madrigal, Francisco , Roos, Annerine , Scheffler, Freda , Stein, Dan J. , Tepper, Ángeles , Ueno, Tsukasa, Undurraga, Juan , Valli, Isabel , Villarreal, Mirta F. , Yalın, Nefize , Zamorano, Francisco , Zanetti, Marcus V. , cVEDA, Pine, Daniel S. , Evans‐Lacko, Sara , Crossley, Nicolás , Murthy, Pratima , Chakrabarti, Amit , Basu, Debasish , Subodh, B. N., Singh, Lenin, Singh, Roshan Lourembam, Kalyanram, Kartik , Kartik, Kamakshi, Kurpad, Sunita Simon , Bharath, Rose Dawn , Orfanos, Dimitri Papadopoulos , Sharma, Eesha , Alliende, Luz María , Medel, Vicente , Bethlehem, Richard A I , Benegal, Vivek , Bernardo, Miquel , Billeke, Pablo , Busatto, Geraldo F , Castro, Mariana N , Czepielewski, Leticia , de la Fuente-Sandoval, Camilo , Duran, Fabio L S , Fittipaldi, Sol , Fornito, Alex , Garani, Ranjini , Guinjoan, Salvador , Ibañez, Agustín , Ivanovic, Daniza , Lochner, Christine , Massuda, Raffael , Miyata, Jun , Mizrahi, Romina , Murray, Robin , Ramirez-Mahaluf, Juan P , Reis Marques, Tiago , Reyes-Madrigal, Francisco , Roos, Annerine , Salum, Giovanni , Stein, Dan J , Tepper, Angeles , Undurraga, Juan , Undurraga, Eduardo A , Valdes-Sosa, Pedro , Valli, Isabel , Zamorano, Francisco , Crossley, Nicolas A , López-Jaramillo, Carlos , Ozerdem, Aysegul , Yalin, Nefize , Zugman, André , Seidlitz, Jakob , Arnatkevičiūtė, Aurina , Bressan, Rodrigo A. , Forti, Marta Di , Díaz‐Caneja, Covadonga M. , Plessis, Stefan S. du , León-Ortíz, Pablo , Luckhoff, Hilmar Klaus , Phahladira, Lebogang , Reckziegel, Ramiro de Freitas Xavier , Rosa-Neto, Pedro , Serpa, Maurício Henriques , Winton‐Brown, Toby , cVEDA, Winkler, Anderson M. , Kartik, Kamakshi , Kumaran, Kalyanaraman , Krishnaveni, Ghattu Vedamurthy , Kuriyan, Rebecca , Barker, Gareth J. , Desrivières, Sylvane , Purushottam, Meera , Hickman, Matthew , Heron, Jon , Toledano, Mireille B. , Vaidya, Nilakshi

Mayo Clinic

Proceedings of the National Academy of Sciences | May 8, 2023 | Volume: 120 | Issue: 20 | Pages: No page available

10.1073/pnas.2218782120 | PMID 37155867 Get It

Gender inequality across the world has been associated with a higher risk to mental health problems and lower academic achievement in women compared to men. We also know that the brain is shaped by nurturing and adverse socio-environmental experiences. Therefore, unequal exposure to harsher conditions for women compared to men in gender-unequal countries might be reflected in differences in their brain structure, and this could be the neural mechanism partly explaining women’s worse outcomes in gender-unequal countries. We examined this through a random-effects meta-analysis on cortical thickness and surface area differences between adult healthy men and women, including a meta-regression in which country-level gender inequality acted as an explanatory variable for the observed differences. A total of 139 samples from 29 different countries, totaling 7,876 MRI scans, were included. Thickness of the right hemisphere, and particularly the right caudal anterior cingulate, right medial orbitofrontal, and left lateral occipital cortex, presented no differences or even thicker regional cortices in women compared to men in gender-equal countries, reversing to thinner cortices in countries with greater gender inequality. These results point to the potentially hazardous effect of gender inequality on women’s brains and provide initial evidence for neuroscience-informed policies for gender equality.
Mucosal Architectural Change is an Important Feature in Distinguishing Crohn's Disease From Others in Terminal Ileum Ulcer Biopsy
Zhong, Tingting , Zhang, Lizhi , Wu, Yanchuang, Pan, Yipeng, Xu, Jiaqi , Cao, Qian , Jiang, Zhinong , Jiang, Zhinong , Tang, Wen , Fu, Yujuan

Mayo Clinic

International Journal of Surgical Pathology | May 2, 2023 | Volume: 32 | Issue: 1 | Pages: 75-82

10.1177/10668969231171135 | PMID 37128682 Get It

Background Besides Crohn's disease (CD), there are a variety of other causes that can also lead to ulcerations in the terminal ileum. The purpose of this study was to identify useful diagnostic features for CD when evaluating terminal ileum biopsies in patients with endoscopic finding of ulcers. Methods Five hundred and seventy-one patients with endoscopic finding of ulcers were included in this retrospective study. Five main histological features were analysed, which were crypt irregularity, mucosal thickening, villous stromal widening (including villous atrophy), granulomas, and pseudopyloric gland metaplasia. Clinical and pathological features were determined by uni- and multivariable logistic regression. Then another independent cohort of 99 patients was established for verifying this nomogram. Results The crypt irregularity, mucosal thickening, and villous stromal widening were combined to be considered as one new variable named mucosal architectural change which was an independent variable in diagnosing CD. We found that mucosal architectural change, age <40 years, the presence of granulomas, and the presence of pseudopyloric gland metaplasia were independent factors for the pathological diagnosis of CD. Then nomogram was developed, with receiver operating characteristic (ROC) curve (area under the ROC curve [AUC] = 0.927) in training sets, and ROC curve (AUC = 0.913) in validation sets. Conclusions We found mucosal architectural change is very helpful in distinguishing CD from non-CD patients. In the context of small biopsy which may lack full scope of changes, the model developed by combining these key features is valuable in predicting a diagnosis of CD, especially in younger patients (age <40 years).
Model‐informed approach to support pediatric dosing for the pan‐PI3K inhibitor copanlisib in children and adolescents with relapsed/refractory solid tumors
Morcos, Peter N. , Schlender, Jan, Burghaus, Rolf , Moss, Jonathan, Lloyd, Adam , Childs, Barrett H. , Macy, Margaret E. , Chung, John, Garmann, Dirk , Schlender, Jan‐Frederik , Moss, Jonathan, Reid, Joel M.

Mayo Clinic

Clinical and Translational Science | April 12, 2023 | Volume: 16 | Issue: 7 | Pages: 1197-1209

10.1111/cts.13523 | PMID 37042099 Get It

AbstractCopanlisib is an intravenously administered phosphatidylinositol 3‐kinase (PI3K) inhibitor which was investigated in pediatric patients with relapsed/refractory solid tumors. A model‐informed approach was undertaken to support and confirm an empirically selected starting dose of 28 mg/m2 for pediatric patients ≥1 year old, corresponding to 80% of the adult recommended dose adjusted for body surface area. An adult physiologically based pharmacokinetic (PBPK) model was initially established using copanlisib physicochemical and disposition properties and clinical pharmacokinetics (PK) data and was shown to adequately capture clinical PK across a range of copanlisib doses in adult cancer patients. The adult PBPK model was then extended to the pediatric population through incorporation of age‐dependent anatomical and physiological changes and used to simulate copanlisib exposures in pediatric cancer patient age groups. The pediatric PBPK model predicted that the copanlisib 28 mg/m2 dose would achieve similar copanlisib exposures across pediatric ages when compared with historical adult exposures following the approved copanlisib 60 mg dose administered on Days 1, 8, and 15 of a 28‐day cycle. Clinical PK were collected from a phase I study in pediatric patients with relapsed/refractory solid tumors (aged ≥4 years). An established adult population PK model was extended to incorporate an allometrically‐scaled effect of body surface area and confirmed that the copanlisib maximum tolerated dose of 28 mg/m2 was appropriate to achieve uniform copanlisib exposures across the investigated pediatric age range and consistent exposures to historical data in adult cancer patients. The model‐informed approach successfully supported and confirmed the copanlisib pediatric dose recommendation.
Abstract 1226: SETD2 loss in renal epithelial cells induces epithelial to mesenchymal transition in a TGFβ-independent manner
Wang, Tianchu , Hlady, Ryan A. , Kim, Sungho , Wagner, Ryan, Pan, Xiaoyu , Ho, Thai H. , Robertson, Keith D.

Mayo Clinic

Cancer Research | April 5, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 1226-1226

10.1158/1538-7445.am2023-1226 Get It

Abstract Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma (RCC) and accounts for majority of the deaths from renal cancer. SETD2, the sole histone methyltransferase that catalyzes trimethylation of lysine 36 on histone H3 (H3K36me3), is frequently mutated in ccRCC. Studies have shown that SETD2 mutations are often subclonal and the mutation rate dramatically increases from 25% in primary ccRCC to more than 60% in metastatic ccRCC, suggesting SETD2 loss plays an important role in renal cancer metastasis. However, mechanisms underpinning how SETD2 mutation drives invasion and metastasis in ccRCC is largely unknown. Here, by performing RNA-seq and ATAC-seq in a non-tumorigenic renal epithelial cell line isogenic for SETD2 loss-of-function, we found that SETD2 inactivation induces dramatic changes in the transcriptome and drastically enhances chromatin accessibility, which allows binding of a variety of transcription factors. We also discovered that SETD2 loss induces a TGFβ-independent EMT program, which is a major pathway linked to metastasis. Correlation of RNA-seq with ATAC-seq identifies SOX2, OCT2 and PRRX1 as key transcription factors promoting the SETD2 loss-driven EMT program. Furthermore, we found that this distinct EMT program is in part triggered by secreted factors, which suggests that SETD2 mutation promotes a metastasis-permissive tumor microenvironment through paracrine signaling. In summary, our findings reveal that SETD2 is a key regulator of EMT phenotypes that may explain the role of SETD2 mutations in ccRCC metastasis and further uncover potential therapeutic targets for SETD2-mutant ccRCC patients. Citation Format: Tianchu Wang, Ryan Wagner, Ryan Hlady, Sungho Kim, Xiaoyu Pan, Thai Ho, Keith Robertson. SETD2 loss in renal epithelial cells induces epithelial to mesenchymal transition in a TGFβ-independent manner [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1226.
International Liver Transplantation Society/Society for Advancement of Transplant Anesthesia Consensus Statement on Essential Attributes of a Liver Transplant Anesthesiologist
Bhangui, Pooja , Pustavoitau, Aliaksei , Sabaté, A. , Wagener, Gebhard , Wray, Christopher , Pan, Terry Ling Te , Nguyen, Christine , Bezinover, Dmitri , Biancofiore, Gíanni , Blasi, Annabel , Chadha, Ryan , Saner, Fuat Hakan , Zerillo, Jeron

Mayo Clinic

Transplantation | March 22, 2023 | Volume: 107 | Issue: 7 | Pages: 1427-1433

10.1097/tp.0000000000004583 | PMID 36944597 Get It

Background. We sought to establish consensus on the essential skills, knowledge, and attributes that a liver transplant (LT) anesthesiologist should possess in a bid to help guide the further training process. Methods. Consensus was achieved via a modified Delphi methodology, surveying 15 identified international experts in the fields of LT anesthesia and critical care. Results. Key competencies were identified in preoperative management and optimization of a potential LT recipient; intraoperative management, including hemodynamic monitoring; coagulation and potential crisis management; and postoperative intensive and enhanced recovery care. Conclusions. This article provides an essential guide to competency-based training of an LT anesthesiologist.
The fifth edition of the World Health Organization Classification and the International Consensus Classification of myeloid neoplasms: evolving guidelines in the molecular era with practical implications
Zheng, Gang , Li, Peng , Zhang, Xiaohui , Pan, Zenggang

Mayo Clinic

Current Opinion in Hematology | February 2, 2023 | Volume: 30 | Issue: 2 | Pages: 53-63

10.1097/moh.0000000000000748 | PMID 36728868 Get It

Purpose of review There have been major advances in our understanding of molecular pathogenesis of myeloid neoplasms, which prompt the updates in the classification of myeloid neoplasms in the fifth edition of World Health Organization Classification (WHO-5) and the new International Consensus Classification (ICC). The purpose of this review is to provide an overview of these two classification systems for myeloid neoplasms. Recent findings The definition, classification, and diagnostic criteria in many myeloid entities have been refined in WHO-5 and ICC with improved understanding of morphology and integration of new genetic findings. Particularly, molecular and cytogenetic studies have been increasingly incorporated into the classification, risk stratification, and selection of therapy of myeloid neoplasms. Overall, despite some revisions and discrepancies between WHO-5 and ICC, the major categories of myeloid neoplasms remain the same. Further validation studies are warranted to fine-tune and, ideally, integrate these two classifications. Summary Integration of clinical information, laboratory parameters, morphologic features, and cytogenetic and molecular studies is essential for the classification of myeloid neoplasms, as recommended by both WHO-5 and ICC.